---
title: "The 3 Best Neuroscience Biotech Stocks to Buy Now"
description: "Problems with the central nervous system are difficult to treat due to complexity and the blood-brain barrier. However, investing in successful neurological drugs can be profitable. The three best neu"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/209328881.md"
published_at: "2024-07-19T11:00:00.000Z"
---

# The 3 Best Neuroscience Biotech Stocks to Buy Now

> Problems with the central nervous system are difficult to treat due to complexity and the blood-brain barrier. However, investing in successful neurological drugs can be profitable. The three best neuroscience biotech stocks to buy now are Vertex, Eisai, and NeuroOne Medical. Vertex has a non-addictive pain medication, suzetrigine, with strong revenue potential. Eisai's Alzheimer's drug, Leqembi, shows promising results and is undervalued. NeuroOne develops products for brain and spinal cord stimulation, partnering with prestigious hospitals.

Problems with the central nervous system are the second leading cause of death globally, the World Health Organization determined in 2022. One reason for this situation is that it’s extremely difficult to develop effective treatments for these disorders because of the complexity of the CNS, European biotech news website *Labiotech* reported last year. Further, the blood-brain barrier that stops damaging substances from entering our brains also prevents many drugs from impacting the organ.

In general, finding safe, effective drugs that insurers will pay for and that will be better than standard-of-care treatments is an extremely long, arduous process that’s unlikely to succeed. Given the enhanced difficulties involved with developing neurological treatments, companies in that space have an even harder road to traverse.

But the good news for investors is that, if companies do develop successful neurological drugs, they probably won’t face much tough competition. With that in mind, here are the three best neuroscience biotech stocks to buy now.

## Vertex (VRTX)

Source: Pavel Kapysh / Shutterstock.com

Pain is a neurological phenomenon. Consequently, **Vertex’s** (NASDAQ:**VRTX**) moderate-to-severe acute pain treatment, called suzetrigine, can be viewed as a neurological drug. Importantly, suzetrigine is a non-opioid pain medication, making it much less addictive than the powerful opioid pain treatments widely used today.

Vertex CEO Reshma Kewalramani explained that his company’s drug can “potentially fill the gap” between very safe but fairly weak painkillers and strong, opioid painkillers that can easily become addictive.

In a Phase-3 trial, suzetrigine successfully reduced patients’ surgical and non-surgical pain meaningfully more than a placebo. However, it failed to lessen patients’ pain significantly more than a combination of the opioid drug hydrocodone and acetaminophen.

Nonetheless, GlobalData has estimated that the drug will generate a significant $1.4 billion of revenue for Vertex in 2030. Other analysts believe that the treatment could generate multi-billion dollar peak annual revenue.

Vertex hoped to finish submitting the drug to the FDA for its approval as a treatment for “moderate to severe pain” by the end of last quarter.

Given the strong potential of Vertex’s non-addictive painkiller, I view it as one of the best biotech stocks to buy at this point.

## Eisai (ESAIY)

Source: PopTika / Shutterstock.com

As I’ve noted in previous columns, **Eisai’s** (OTCMKTS:**ESAIY**) Alzheimer’s drug, Leqembi, actually improved the cognition capabilities of 60% of patients thought to be in the early stages of the disease.

Meanwhile, in May Eisai began a rolling submission of a Biologics License Application (BLA) for a subcutaneous version of the drug. If approved, this version, unlike the intravenous version that’s already being utilized, can be administered to patients in doctors’ offices and in homes. Additionally, the drug can be delivered more quickly via the subcutaneous mechanism than through IV, Eisai reported. Given these points, I believe that the demand for Leqembi will greatly increase after the subcutaenous version of it is released.

By fiscal 2026, Eisai predicts that the drug’s sales can reach almost $2 billion in its fiscal year that ends in March 2027 and $8.8 billion in its fiscal year that ends in March 2033.

Given Leqembi’s strong efficacy and the lack of strong competition in the Alzheimer’s treatment space, I believe that the drug’s revenue can significantly exceed those targets. Consequently, I believe that the company, which currently has a market capitalization of almost $12 billion, is significantly undervalued and is one of the best biotech stocks to buy now.

## NeuroOne Medical (**NMTC**)

Source: everything possible / Shutterstock.com

**NeuroOne** (NASDAQ:**NMTC**) develops products using thin film electrode technology. Its offerings are being used to facilitate electroencephalograms or EEGs which determine the extent of electrical activity in the brain. NeuroOne’s products are also being used in conjunction with spinal cord stimulation and brain stimulation.

Provoiding significant validation for NeurOne and its products, the firm partners with two very prestigious hospitals, Mayo Clinic and Cleveland Clinic. Additionally, the firm collaborates with a huge medical device company, **Zimmer Biomet** (NYSE:**ZBH**).

Also impressively, NeuroOne is only nine healthcare firms whose stock is owned by the Mayo Clinic.

Moreover, NeuroOne is growing at an impressive rate as its product revenue jumped to $1.38 million last quarter compared to $466,000 during the same period a year earlier.

*On the date of publication, Larry Ramer held a long position in ESAIY. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines*.

*On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.*

Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been SMCI, INTC, and MGM. You can reach him on Stocktwits at @larryramer.

Healthcare, Biotech

### Related Stocks

- [VERX.US - Vertex](https://longbridge.com/en/quote/VERX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 發展黃金市場為今年重頭戲 許正宇：逾十銀行加入港金結算公司理事會 | 香港財經事務及庫務局局長許正宇表示，發展黃金市場是今年的重點，已與上海黃金交易所籤署合作協議，成立港金結算公司，預計年內啟動運作。超過 10 家銀行已確認加入理事會，目標是開發香港的黃金中央清算系統。此外，香港新股市場活躍，但對新股質素的關 | [Link](https://longbridge.com/en/news/276291952.md) |
| 張德熙料金價未來兩季挑戰 6000 美元 港金所夥阿里開發交易平台 | 香港黃金交易所舉行新春開市儀式，金價為 46,518 元，預計未來兩季將挑戰每盎士 6,000 美元。張德熙表示，金價在牛市初中期，若發生美伊戰爭將小幅調整後再上升。交易所與阿里巴巴合作開發國際貴金屬交易平台，提供多種交易服務，並計劃推出  | [Link](https://longbridge.com/en/news/276406795.md) |
| 百本積極開拓新業務 醫護培訓去年錄兩位數增長 料僱傭服務增長較快 | 百本醫護（2293）去年積極開拓社區藥房、牙科和僱傭服務等新業務，醫護培訓業務錄得兩位數增長。主席奚曉珠表示，僱傭服務處於起步階段，預計增長較快。公司計劃於今年第 4 季推行社區藥房，認為中標機會大。去年收購 SPDR 金 ETF，閒置現金 | [Link](https://longbridge.com/en/news/276029412.md) |
| 馬年金鈔熱銷賣斷市 僅售千元 大讚好過現金利是「紀念理財一舉兩得」 | 隨著農曆馬年到來，深圳水貝市場迎來黃金消費高峰，1 克重的「馬年紀念金鈔」成為熱銷產品，現已全線斷貨。金價回調後，消費者需求迅速釋放，傳統金飾和小克重吊墜也受到歡迎。各大銀行推出的金鈔產品同樣熱賣，結合傳統習俗與保值需求，金鈔銷售火爆。 | [Link](https://longbridge.com/en/news/276089886.md) |
| 億萬富翁 Dan Loeb 目前鍾愛的 1 只核能股票 | 1 只億萬富翁丹·洛布現在鍾愛的核能股票 | [Link](https://longbridge.com/en/news/276370391.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
